ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

formoterol

Also written as “Formoterol Fumarate”, “budesonide/formoterol” and “Formoterol”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic · Asthma, Exercise-Induced, led by 18 companies.

Drug pageFormoterol: every studyMany companies study it; this page follows only the 137 they lead. All 190 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 4, 2006137 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only632 open or runningphase 4since Jan 4, 2006Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Chiesi Farmaceuticiits history only200 open or runningphase 4since Nov 29, 2010Oct 30, 2006none ahead
Viatrisits history only160 open or runningphase 4since Nov 29, 2011Sep 13, 2005none ahead
Novartisits history only60 open or runningphase 4since Jul 26, 2005Jul 26, 2005none ahead
Sumitomo Pharmaits history only60 open or runningphase 4since Jan 17, 2007Jul 8, 2003none ahead
SkyePharma50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Mundipharmaits history only30 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Mar 9, 2011Mar 9, 2011none ahead
Boehringer Ingelheimits history only20 open or runningphase 2since Sep 11, 2014Sep 11, 2014none ahead

Also a collaborator on its studies: Parexel, CISCRP, eResearchTechnology, Menarini Group, Integrated Therapeutics Group and Pacira BioSciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of SkyePharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2006First studies: 4 phase 3 studies in AsthmaFirst studyNCT00394199, NCT00394121, NCT00393991 and 1 more
  2. Jan 26, 2009Phase 2 study in AsthmaNCT00830102 · 64 enrolled · Ireland, United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 SkyePharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00830102Asthma · Ireland, United Kingdom2CompletedJan 200564
NCT00394199Asthma · United States, Canada3CompletedFeb 2008357
NCT00394121Asthma · Germany, Hungary, Poland and more3CompletedJul 2007400
NCT00393991Asthma · United States, Canada3CompletedApr 2008475
NCT00393952Asthma · United States, Puerto Rico3CompletedApr 2008557

How it is read

Names in the registry

  • “Formoterol Fumarate”, 14 entries
  • “budesonide/formoterol”, 10 entries
  • “Formoterol”, 9 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.